€77.8 0.3 0.3%
Last Trade - 11:45am
| Market Cap | ÂŁ12.62bn |
| Enterprise Value | ÂŁ13.57bn |
| Revenue | ÂŁ4.60bn |
| Position in Universe | 57th / 847 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3,876 | 4,147 | 4,530 | 4,632 | 4,913 | 5,347 | 5,576 | 5,488 | +6.6% | ||
| +32.7 | +67.1 | +57.4 | +1.1 | +4.4 | -1.8 | +28.9 | +3.34 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | January 2, 1987 |
| No. of Shareholders: | n/a |
| No. of Employees: | 8,409 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | BEL 20 , FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Eurozone , FTSEurofirst 300 Ex UK, |
| Exchange | Euronext - Brussels |
| Shares in Issue | 189,025,436 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Allee de la Recherche 60, ANDERLECHT, 1070, Belgium |
| Web | https://www.ucb.com |
| Phone | +32 2 5599999 |
| Contact | Antje Witte (VP Investor Relations) |
| Auditors | PwC Bedrijfsrevisoren BCVBA |
As of 11:45am, shares in Ucb SA are trading at €77.8, giving the company a market capitalisation of £12.62bn. This share price information is delayed by 15 minutes.
Shares in Ucb SA are currently trading at €77.8 and the price has moved by -14.96% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ucb SA price has moved by -23.22% over the past year.
Of the analysts with advisory recommendations for Ucb SA, there are there are currently 5 "buy" , 7 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ucb SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Ucb SA is scheduled to issue upcoming financial results on the following dates:
The Ucb SA dividend yield is 1.15% based on the trailing twelve month period.
Last year, Ucb SA paid a total dividend of 0.89, and it currently has a trailing dividend yield of 1.15%. Looking ahead, shares in Ucb SA are due to go ex-dividend on 2021-04-30 and the next dividend pay date is 2021-05-04.
Ucb SA are due to go ex-dividend on 2021-04-30 and the next dividend pay date is 2021-05-04. The historic dividend yield on Ucb SA shares is currently 1.15%.
To buy shares in Ucb SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Ucb SA are currently trading at €77.8, giving the company a market capitalisation of £12.62bn.
Here are the trading details for Ucb SA:
Based on an overall assessment of its quality, value and momentum, Ucb SA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Ucb SA are currently priced at €77.8. At that level they are trading at 38.32% discount to the analyst consensus target price of 0.00.
Analysts covering Ucb SA currently have a consensus Earnings Per Share (EPS) forecast of 5.573 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ucb SA. Over the past six months, the relative strength of its shares against the market has been -27.52%. At the current price of €77.8, shares in Ucb SA are trading at -17.94% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ucb SA PE ratio based on its reported earnings over the past 12 months is 17.93. The shares are currently trading at €77.8.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ucb SA's management team is headed by:
Here are the top five shareholders of Ucb SA based on the size of their shareholding:
